AcelRx Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
AcelRx Pharmaceuticals Stock Forecast and Price Target
The average price target for AcelRx Pharmaceuticals's stock lately set by several renowned analysts is $5.13, which would result in a potential upside of approximately 428.87% if it reaches this mark by December 31, 2024. This estimation is based on a high estimate of $6.00 and a low estimate of $4.25. Even if you are not interested in ACRX stock, you should still be aware of its competitors.
428.87% Upside
AcelRx Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
AcelRx Pharmaceuticals's Price has increased by 100.00% In the last three years, going from $0.00 to $0.00. In the next year, analysts expect Fair Value to reach $1.04 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$148.53 | Buy/Sell | $174.55 | 14.45% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Buy |
14
|
$8.10 | Buy/Sell | $17.83 | 109.88% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$30.26 | Buy/Sell | $41.00 | 32.19% |
| ANIP Stock Forecast | ANI Pharmaceuticals | Buy |
13
|
$65.43 | Buy/Sell | $69.75 | 22.27% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$25.90 | Buy/Sell | $47.90 | 73.75% |
AcelRx Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last two years, AcelRx Pharmaceuticals's Revenue has decreased from $5.42M to $650.00k – a 88.01% drop! In the next year, analysts expect Revenue to reach $680.00k – an increase of 4.62%. For the next seven years, the forecast is for Revenue to grow by 3994.02%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| COLL Stock Forecast | Collegium Pharmaceutical | Outperform |
11
|
$35.48 | Buy/Sell | $37.75 | 12.74% |
| HRTX Stock Forecast | Heron Therapeutics | Buy |
7
|
$2.65 | Buy/Sell | $5.63 | 145.28% |
| AQST Stock Forecast | Aquestive Therapeutics | Buy |
0
|
$3.90 | Buy/Sell | $6.33 | 130.77% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ZVRA Stock Forecast | Zevra Therapeutics | Buy |
10
|
$4.56 | Buy/Sell | $19.50 | 305.70% |
| DRRX Stock Forecast | DURECT | Outperform |
9
|
$0.88 | Buy/Sell | $6.75 | 667.05% |
| CPIX Stock Forecast | Cumberland Pharmaceuticals | - |
0
|
$2.03 | Buy/Sell | $8.50 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ACOR Stock Forecast | Acorda Therapeutics | - |
5
|
$0.43 | Buy/Sell | $200.00 | -100.00% |
| TRVN Stock Forecast | Trevena | Outperform |
2
|
$0.61 | Buy/Sell | $5.18 | 555.74% |
| BXRX Stock Forecast | Baudax Bio | - |
0
|
$0.01 | Buy/Sell | $24.00 | -100.00% |
AcelRx Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, AcelRx Pharmaceuticals's EBITDA has fallen from $-39.11M to $-16.58M – a 57.61% decrease. Next year, analysts are expecting EBITDA to reach $-22.35M – an increase of 34.83%. Over the next seven years, the forecast is for EBITDA to grow by 41.76%.
AcelRx Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
AcelRx Pharmaceuticals's EBIT has decreased In the last three years, from $-40.96M to $-16.89M – a 58.76% drop. For next year, analysts predict EBIT of $-19.94M, which would mean an increase of 18.06%. Over the next seven years, experts predict that AcelRx Pharmaceuticals's EBIT will grow at a rate of 367.80%.
AcelRx Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
AcelRx Pharmaceuticals's EPS has increased by 100.00% In the last three years, going from $-9.40 to $0.00. In the next year, analysts expect EPS to reach $-0.92 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
Site Navigation
.jpg)